Adaptimmune Therapeutics plc (ADAP)

Adaptimmune Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 20, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	155	180	239	586	834	126
Market Cap Growth	37.78%	-24.70%	-59.17%	-29.79%	561.07%	-79.01%
Enterprise Value	43	44	62	372	458	48
Last Close Price	0.60	0.79	1.46	3.75	5.39	1.20
PS Ratio	0.85	2.99	8.81	95.26	210.78	112.48
PB Ratio	1.93	4.56	2.92	2.84	2.44	1.02
P/TBV Ratio	3.21	4.60	2.94	2.86	2.46	1.04
P/FCF Ratio	-	-	-	271.82	-	-
P/OCF Ratio	-	-	-	54.60	-	-
EV/Sales Ratio	0.25	0.73	2.28	60.44	115.73	43.03
EV/FCF Ratio	-	-	-	172.44	-	-
Debt / Equity Ratio	0.93	0.64	0.28	0.12	0.07	0.21
Debt / FCF Ratio	-	-	-	11.82	-	-
Asset Turnover	0.57	0.20	0.07	0.01	0.01	0.00
Inventory Turnover	87.81	97.02	126.15	78.45	51.66	76.59
Quick Ratio	3.54	2.66	3.76	6.45	9.96	3.17
Current Ratio	3.85	2.85	3.96	6.64	10.19	3.51
Return on Equity (ROE)	-52.96%	-187.61%	-114.96%	-57.78%	-55.97%	-74.04%
Return on Assets (ROA)	-7.68%	-28.22%	-25.31%	-22.03%	-26.36%	-38.12%
Return on Capital (ROIC)	-17.59%	-101.68%	-60.08%	-34.01%	-32.44%	-44.12%
Earnings Yield	-28.76%	-63.22%	-69.17%	-26.99%	-15.59%	-108.69%
FCF Yield	-35.64%	-80.82%	-71.60%	0.37%	-6.70%	-90.41%
Buyback Yield / Dilution	-32.34%	-24.73%	-3.47%	-9.36%	-35.72%	-7.78%
Total Shareholder Return	-32.34%	-24.73%	-3.47%	-9.36%	-35.72%	-7.78%

Source: S&P Capital IQ. Standard template. Financial Sources.